AstraZeneca Collaborates with Qure.ai for AI-Based Lung Cancer Diagnosis Pilot Trial

AstraZeneca has announced a new team-up with Qure.ai and a UK-based clinical team in a pilot trial to test the diagnostic capabilities of Qure.ai’s qXR software in identifying lung cancer from X-ray images. The trial will be held in clinics in Greater Manchester, which is noted for having some of the highest lung cancer rates in the nation.

According to Phil Taylor, “qXR has been trained on more than 2 million X-rays and their corresponding radiology reports, using deep-learning algorithms to interpret the images. It classifies them as remarkable or unremarkable, detects and localises up to 29 abnormalities, and highlights them on the image for review by the radiologist. A study conducted by Qure.ai demonstrated a 17% improvement in sensitivity when using AI to interpret chest X-rays, compared to radiologist readings.”

To read more, click here.

(Source: PharmaPhorum, January 17^th, 2023)